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Background: Emerging data suggests that chronic inﬂammatory disease, such as psoriasis, may be
associated to coronary artery disease (CAD). Objective: Analyze the association between psoriasis and
subclinical atherosclerosis using coronary calcium score (CAC). Methods: We investigated 221 partici-
pants with psoriasis and 718 age- and sex-matched controls without prior known CAD. All participants
completed a questionnaire and underwent laboratory tests and a CAC exam. Logistic regression models
adjusted for Framingham risk score (FRS) and C-reactive protein (hs-CRP) were built. CAC was included
in the models as a binary variable with different cut off values. Results: Body-mass index, race, hyper-
tension, HDL, LDL and hs-CRP were signiﬁcantly associated with psoriasis presence and severity. Psoriasis
severity was signiﬁcantly associated with CAC (p ¼ 0.04), particularly for very high CAC (>400) (p < 0.01).
The OR for severe psoriasis and CAC >400 was 2.45 (95%CI: 1.26e4.75) in unadjusted models. In a model
adjusted for the FRS, this association was no longer signiﬁcant, but a trend was noted (p ¼ 0.09). No
signiﬁcant changes in the association were noted after the inclusion of hs-CRP in the model. Conclusion:
Psoriasis is associated with higher CAC values, mainly in individuals with severe psoriasis. The current
ﬁndings also suggest the potential involvement of other mechanisms beyond classical cardiovascular risk
factors and inﬂammation in this association.
© 2014 Elsevier Ireland Ltd. All rights reserved.Introduction
Psoriasis is a common chronic inﬂammatory disease with
prevalence of 2e4% among adults in the U.S. and Europe [1,2]. Its
presentation is most commonly mild and limited to skin lesions;
however, more severe cases can include extensive skin and joint
involvement, resembling other chronic inﬂammatory diseases,
such as rheumatoid arthritis and systemic lupus erythematosus [3].
While substantial data supports the association of both rheumatoid
arthritis [4] and lupus [5] with early atherosclerosis development
and increased incidence of cardiovascular disease [6] and mortality
[7], this association is less clear for psoriasis. A recent systematic
review found that patients with psoriasis had a higher prevalence
of cardiovascular risk factors and an increased rate ofidemiological Research, Hos-
~ao Paulo, SP, CEP 05508-000,
, isabensenor@gmail.com
rved.cardiovascular events. Moreover, other emerging data suggest that
cardiovascular risk in these patients might be independent of
traditional cardiovascular risk factors [8].
Coronary artery calcium (CAC) is a well-validated marker of
subclinical coronary atherosclerosis, which is strongly associated
with future cardiovascular events [5]. Furthermore, CAC provides
risk information that is incremental to traditional risk factors [6]d
thus improving risk discrimination beyond clinical risk scores, such
as Framingham [7,8]. Interestingly, a recent study has demon-
strated that the Framingham risk score may underestimate the
extent of disease in patients with psoriasis [9]. However, only one
small cross-sectional study evaluated the association of psoriasis
and CAC score, demonstrating higher CAC score in patients with
psoriasis compared to controls [10]. Nevertheless, due to the small
sample size the study was not powered to adjust for CAD risk fac-
tors. Thus, it remains unclear if psoriasis provides additional car-
diovascular risk beyond traditional risk factors [11,12]. Therefore, in
the present study, we have evaluated whether psoriasis is inde-
pendently associated with subclinical atherosclerosis as detected
by CAC.
H.L. Staniak et al. / Atherosclerosis 237 (2014) 847e852848Methods
The Coronary Artery Calcium in Psoriasis (CALIPSO) Study is a
cross-sectional study evaluating the frequency of cardiovascular
risk factors, and subclinical atherosclerosis in patients with psori-
asis compared to controls. An internal review board approved the
study, and all participants signed an informed consent.
Each participant had been diagnosed with psoriasis at least
three years prior to entering the study. An expert dermatologist in a
referral outpatient clinic evaluated the cases of psoriasis. Disease
involvement of each participant was assessed by calculation of the
standardized Psoriasis Area Severity Index (PASI) [13]. Psoriasis
cases were classiﬁed as mild or severe based on the use of systemic
medication for psoriasis treatment: mild cases were deﬁned as
individuals who were not using systemic treatment for psoriasis
and had a PASI score below 7 at the initial evaluation, while severe
cases were deﬁned as patients currently on systemic medications
or with a PASI score greater than 7 at the initial evaluation. Each
patient with psoriasis was age and gender matched to up to four
selected participants with no history of psoriasis from the Brazilian
Longitudinal Study of Adult Health (ELSA-Brasil), an ongoing cohort
study evaluating factors associated with cardiovascular disease and
diabetes in a multicentre sample of six sites in Brazil [14].
All study participants underwent a structured clinical evalua-
tion that included screening for current presence of cardiovascular
disease with speciﬁc questions about angina, myocardial infarction,
and revascularization (percutaneous or surgical) and a 12-lead rest
electrocardiogram. Patients with and without psoriasis were
excluded from the sample if they had prior history of cardiovascular
disease, as well as if they presented ischemic ECG abnormalities.
Similarly, patients with other systemic diseases were excluded.
Sample size
The sample has a power of 80% to detect an odds ratio (OR) of 3.7
using the group of individuals free of psoriasis as the reference; andTable 1
General characteristics of patients with psoriasis and age- and sex-matched psoriasis-fre
All No psoriasis
n ¼ 939 n ¼ 718
Age (years) 55.8 (8.3) 55.8 (8.1)
Body mass index (kg/m2) 28.0 (5.1) 27.4 (4.7)*
Women (%) 467 (49.7) 362 (50.4)
Race
White 264 (28.1) 92 (13.1)
Brown 183 (19.9) 155 (22.0)
Black 418 (44.5) 414 (48.9)
Other 74 (7.5) 55 (7.6)
Education
<11 years 162 (17.3) 126 (17.6)
11 years 775 (82.7) 591 (82.4)
Hypertension (%) 390 (45.6) 327 (45.5)
Diabetes (%) 192 (20.5) 147 (20.5)
Dyslipidaemia (%) 585 (62.4) 445 (62.1)
Metabolic syndrome 477 (50.9) 372 (51.8)
Smoking (%) 141 (15.1) 114 (15.9)
HDL-C mg/dl 54.3 (15.4) 55.9 (15.5)*
LDL-C mg/dl 128.9 (34.5) 132.3 (34.4)*z
Triglycerides mg/dl 140.6 (88.5) 138.0 (81.1)
Hs-CRP mg/dl 3.2 (4.8) 2.9 (4.5)
FS CHD 10 years (%) 8.5 (6.1) 8.5 (6.0)
CAC ¼ 0 552 (58.8) 423 (58.9)
CAC 1e100 243 (25.9) 192 (26.7)
CAC 101e400 98 (10.4) 74 (10.3)
CAC > 400 46 (4.9) 29 (4.0)
*P < 0.05 for the difference between participants without psoriasis and those with seve
psoriasis P < 0.05; zparticipants without psoriasis are different from patients with mild ps
10 years.considering a frequency of altered calcium score of 0.59 in patients
with psoriasis and of 0.28 in psoriasis free individuals. The fre-
quency of altered CAC was based on previous studies in literature
[10]. We considered a a of 0.05. Sample power was calculated using
SPSS Sample Power.
Data collection
All participants answered an extensive questionnaire regarding
previous and family history of hypertension, diabetes, dyslipidae-
mia, coronary heart disease, angina, myocardial infarction, revas-
cularization (percutaneous or surgery), education, smoking.
Anthropometric parameters were measured using standard
equipment and techniques [15]. A standard 12-lead ECG was per-
formed. Blood samples were collected after a 12-h overnight fast. A
standard 75-g oral glucose tolerance test was administered to all
participants without previous diagnosis of diabetes. Hypertension
was deﬁned as the presence of one of the following: medical his-
tory of hypertension diagnosis, use of anti-hypertensive treatment,
systolic blood pressure 140 mm Hg, or diastolic blood pressure
90 mm Hg. Diabetes was deﬁned as the presence of one of the
following: medical history of diabetes diagnosis, use of oral hypo-
glycaemic treatment or insulin, fasting plasma glucose126 mg/dl,
or 2-h oral glucose tolerance test 200 mg/dl. Dyslipidaemia was
deﬁned as the presence of one of the following: medical history of
dyslipidaemia diagnosis, use of lipid-lowering treatment, HDL
cholesterol <40 mg/dl, LDL cholesterol 160 mg/dl, or triglycerides
>150 mg/dl. We also calculated the Framingham Risk Score for
coronary heart disease (CHD), which estimates the 10-year risk of
myocardial infarction or CHD-related death based on age, sex,
smoking status, systolic blood pressure, total cholesterol, and HDL
cholesterol [16].
The following methods were used for each laboratory test.
Fasting Glucose was estimated by a hexokinase method. Total
cholesterol, HDL cholesterol, and triglycerides were evaluated by
enzymatic colorimetric assays, with glycerol phosphate peroxidasee participants.
Mild psoriasis Severe psoriasis p
n ¼ 71 n ¼ 150
55.9 (8.7) 55.6 (9.1) 0.92
29.1 (6.0) 29.9 (6.0) <0.001
32 (45.1) 73 (48.7) 0.66
<0.001
53 (79.1) 119 (79.3)
9 (13.4) 19 (12.7)
1 (1.5) 3 (2.0)
8 (12.0) 9 (6.0)
0.61
14 (19.7) 22 (14.8)
57 (80.3) 127 (85.2)
18 (25.3) 37 (24.7) <0.001
10 (14.1) 35 (23.3) 0.28
48 (67.6) 92 (61.3) 0.63
33 (47.1) 72 (48.3) 0.59
13 (18.8) 14 (9.7) 0.11
51.8 (15.5) 47.8 (12.7) <0.001
122.5 (33.5) 115.5 (31.6) <0.001
154.6 (89.5) 146.5 (117.1) 0.21
4.0 (4.8) 4.3 (5.8) <0.001
8.4 (5.1) 8.8 (7.0) 0.83
36 (50.7) 93 (62.0) 0.04
21 (29.6) 30 (20.0)
11 (15.5) 13 (8.7)
3 (4.2) 14 (9.3)
re psoriasis; yparticipants without psoriasis are different from patients with severe
oriasis P < 0.05; #FS CHD 10 years: Framingham Score for Coronary Heart Disease in
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dewald Equation, except in participants with triglycerides
>400 mg/dl, for whom LDL cholesterol was estimated by an enzy-
matic colorimetric assay. High-sensitivity C-reactive protein (hs-
CRP) was assessed by immunochemistry (nephelometry) (Dade
Bhering, Siemens®). Distribution of hs-CRP was skewed and thus
were log-transformed before analysis to achieve normality. Values
in Table 1 were back-transformed to return to the natural scale.Coronary artery calcium score
All participants underwent a CAC examination performedwith a
64-detector computed tomography scanner (Brilliance 64, Philips
Healthcare, Best, Netherlands). After the scout images, each patient
also underwent an ECG-gated prospective calcium score exami-
nation with a tube potential of 120 kV and a tube current of 55 mA.
Images were reconstructed using standard ﬁltered back projection,
and the CAC was expressed as Agatston units and percentile [17].
CAC was evaluated in a blinded fashion by an experienced cardi-
ologist using semiautomatic software (Calcium Scoring, Philips
Workstation). The CAC score was further categorized into three
groups: 0, 1e100, 101e400, >400.Statistical analysis
All categorical variables are presented as numbers and pro-
portions, and were compared using the Chi-square test. All
continuous variables are presented as means and standard de-
viations or medians with interquartile intervals, and were
compared using ANOVA or non-parametric tests as indicated.
Since CAC has an extremely skewed distribution, and the pre-
sent sample had amajority of individuals with CAC¼ 0, we chose to
evaluate the association between psoriasis and CAC using logistic
regression. Models were built using coronary artery calcium as a
binary variable (CAC ¼ 0 vs. CAC >0; CAC <100 vs. CAC >100, and
CAC <400 vs. CAC >400). The model included multivariate adjust-
ment for age, gender and risk factors for CAD using the Framingham
Risk Score (FRS) as a summary variable. The use of a summary
variable allows adjustment for a combination of an extensive
number of parameters while maintaining a parsimonious model.
Additionally, this strategy prevents over ﬁtting of model to current
data. A second model was adjusted for the FRS and hs-CRP to
explore the potential role of inﬂammation as an additional risk
marker in the population with psoriasis.Fig. 1. Coronary artery calcium (CAC) distribution across the three groups. P ¼ 0.04 for
the three group comparison.Results
The study initially selected 246 patients with psoriasis and 748
participants without psoriasis. Of these groups, 25 (10.2%) psoriasis
patients and 30 (4.0%) without psoriasis were excluded from the
analysis due to presence of previous cardiovascular disease. The
ﬁnal sample included 221 patients with psoriasis and 718 control
participants (Table 1).
As illustrated in Fig. 1, individuals with psoriasis had a higher
BMI, were more often black, less likely to be hypertensive and had
lower HDL and LDL levels. Additionally, as expected, hs-CRP, a
marker of inﬂammation was higher in individuals with psoriasis.
The CAC distribution across the three groups was signiﬁcantly
different between the three groups (p ¼ 0.04). Notably, individuals
with severe psoriasis were more likely to have very high CAC
(>400).
In the logistic regression models using CAC >0 as the outcome,
no difference between mild (p ¼ 0.18) or severe psoriasis (p ¼ 0.48)
was noted when compared to controls. Similar results were seen
after adjustment for the FRS as well as for the simultaneous
adjustment for FRS and hs-CRP (Fig. 2A). Similar non-signiﬁcant
ﬁndings occurred when CAC >100 was used as the primary
outcome (Fig. 2B).
When CAC >400 was used as the outcome, the ORwas 2.45 (95%
CI: 1.26e4.75) for individuals with severe psoriasis when compared
to controls, whereas individuals with mild psoriasis had an OR of
1.05 (95%CI: 0.31e3.53) when compared to controls. Interestingly,
most of this associationwas attenuated when the FRS was included
in the model (OR 1.89, 95%CI: 0.90e3.99) for individuals with se-
vere psoriasis. The subsequent inclusion of hs-CRP did not provide
any additional change in the OR for this group (OR: 1.91, 95%CI:
0.90e4.04).
Discussion
The results of the present study demonstrate that psoriasis was
associated with CAD as detected by CAC score, particularly for in-
dividuals with severe psoriasis. Interestingly this association was
not driven by an increase in the prevalence of CAC, as no difference
was noted when CAC¼ 0 was used as a cut off. Severe psoriasis was
associated with increased odds of very high CAC (>400). Our results
also support that most, if not all, of this association is mediated by
higher prevalence of traditional risk factors for CAD, as this ﬁnding
was strongly attenuated by the inclusion of the FRS in the logistic
regression model. Finally, although individuals with psoriasis pre-
sented with higher hs-CRP at the initial evaluation, the subsequent
inclusion of this parameter in the model did not interfere with the
results, failing to document inﬂammation as the mediator of the
association of psoriasis and CAC.
Prior studies have demonstrated the association of psoriasis
with subclinical atherosclerosis using carotid artery intima-media
thickness (IMT) as a measure of subclinical cardiovascular disease
compared to matched controls [18e26]. Those studies have re-
ported a positive association between psoriasis and increased ca-
rotid IMT. Yet only two studies to date have evaluated CAC score in
subjects with andwithout psoriasis [10,27]. Ludwig et al. studied 32
patients with psoriasis and matched controls, and reported a
signiﬁcantly increased frequency of CAC >0 in patients compared to
in controls [10]. Yiu et al. evaluated 70 patients with psoriasis and
matched controls, and found a signiﬁcantly increased prevalence
and severity of CAC in patients with psoriasis compared to in
controls after multivariate adjustment [27]. Although our study
partially supports those ﬁndings, we were able to build on those
prior studies and ﬁnd two interesting additional nuances of the
association, which have not yet been demonstrated.
Fig. 2. Multivariable logistic regression models for the prediction of CAC > 0 (panel A), CAC > 100 (panel B) and CAC > 400 (panel C). Only the group with severe psoriasis was
signiﬁcantly associated with CAC > 400 when compared to controls in the unadjusted model. No other comparisons were signiﬁcant for a p < 0.05.
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with psoriasis according to the severity of their disease. Although
several studies have reported a doseeresponse relationship be-
tween cardiovascular risk factors and disease severity [28e30],
none has documented the association of disease severity with
subclinical atherosclerosis, as our data supports. Importantly, a
long-term specialist in psoriasis evaluated all cases, and a well-
validated score was used to grade the disease. At this step, those
ﬁndings are exploratory, and additional studies on the relationship
of psoriasis and CAD are needed to conﬁrm those ﬁndings. Since the
association of psoriasis severity and CAC was not strong, either a
more adequate measure of disease severity is needed, or disease
severity may not play such a signiﬁcant role in the cardiovascular
risk as previously proposed.
The second interesting ﬁnding of our study is that there was no
inﬂuence of hs-CRP on the relationship between psoriasis and CAC.
Most of the studies documenting the association between psoriasis
and atherosclerosis propose that the increased inﬂammatory state
is responsible for the incremental cardiovascular risk [31], though
this remains unproven. Since the value of inﬂammatory markers
change over time, our results should only be considered explor-
atory at this point. Individuals who currently have low hs-CRP may
only be currently more controlled for their psoriasis. Still, no
marker of chronic inﬂammation is currently available. Even though
additional studies are needed to further investigate the role of
inﬂammation on the development of CAD in individuals with
psoriasis, our current results have a very relevant practical impli-
cation. Although hs-CRP is a well-recognized marker of increased
cardiovascular risk, we should not assume it would be a better
predictor of CAD in individuals with systemic inﬂammatory dis-
eases, such as psoriasis until further evidence supports its use.
Our study must, however, be read in the context of its design. As
a cross-sectional study, we are not able to evaluate a causal rela-
tionship between our exposure and the outcomes. Similarly, since
psoriasis severity and hs-CRP change over time, the current data is
insufﬁcient to allow adequate evaluation of the individual exposure
to psoriasis disease and inﬂammation during each individual's
lifetime.
Our present results suggest an association between subclinical
atherosclerosis and psoriasis, mainly for individuals with severe
psoriasis. The current ﬁndings also suggest the potential involve-
ment of other mechanisms beyond classical cardiovascular risk
factors and inﬂammation in this association.Conﬂict of interest
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